Latest news


Resignation of Chief Business Development Officer

Posted on Feb 28, 2019

Oslo (Norway), 28 February 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that its Chief Business Development Officer (CBDO), Gaël L’Hévéder has resigned and will leave PCI Biotech as per end of March 2019 to pursue other career opportunities. “We regret Gaël’s departure but respect his decision,” says Per Walday, […]

Capital increase registered and listing of new shares

Posted on Feb 25, 2019

Oslo, Norway, 25 February 2019. Reference is made to the previous announcements by PCI Biotech Holding ASA (“PCI Biotech” or the “Company”) in respect of the issuance of 61,000 new shares following exercise of employee share options in the Company. The share capital increase resolved by the Board of Directors following the share option exercise […]

Exercise of employee share options, mandatory notification of trade and resolution to increase share capital

Posted on Feb 20, 2019

Oslo (Norway), 20 February 2019 – Exercise of employee share options, mandatory notification of trade and resolution to increase the share capital in PCI Biotech Holding ASA (the “Company”). Options exercised and mandatory notification of trade on 20 February 2019 Participants in the Company’s share option program have on 20 February 2019 exercised a total […]